FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290391409> ?p ?o ?g. }

• W4290391409 endingPage "15" @default.
• W4290391409 startingPage "4" @default.
• W4290391409 abstract "Background. The current trend of growing antibiotic resistance among pathogenic microorganisms remains one of the urgent and significant problems of mankind. The constant spread of resistant strains of microorganisms requires the development of innovative methods and the search for medicinal compounds with a highly effective mechanism of action. One of these multi-resistant pathogens that are difficult to eradicate is the causative agent of tuberculosis — Mycobacterium tuberculosis. The aim is to study the effect of newly synthesized pyrimidine derivatives on the growth of Mycobacterium tuberculosis culture, as well as on the structural changes in cells. Material and methods. In order to assess the effect of a number of pyrimidine derivatives on the growth of Mycobacterium tuberculosis culture, 6 samples of 5-(arylmethylene) hexahydropyrimidine-2,4,6-triones (TAG1 — TAG6), 7 samples of 5-hetarylmethylidene-2,4,6-triones (TAG7 — TAG13), and 2 new samples of 3-(2-Benzyloxy-2-oxoethyl)quinazoline-4(3H)-one and 3-[2-(1-Naphthyl)-2-oxoethyl]quinazoline-4(3H)-one were screened under the laboratory ciphers VMA-13-03 and VMA-13-04 in the course of the study. M.tuberculosis H37RV strain was used as a test culture; it was provided by the bacteriological laboratory of the Regional Infectious Clinical Hospital named after A. M. Nichoga. A 4-week culture of M.tuberculosis, synchronized by cold (+4°C) for 72 hours, was used to prepare a suspension of mycobacteria. The number of mycobacteria in the suspension was determined using the McFarland 0.5 turbidity standard. 0.2 ml of M.tuberculosis working suspension was added to each tube of a series of successive dilutions of the studied substances, including the control. The study was carried out in 4 series of replicates. The minimum bactericidal concentration of the compounds, at which no colony growth was detected, as well as the minimum inhibitory concentration, at which mycobacterium growth was delayed by 50% compared to the control, were determined. Smears were prepared from the sediment for staining using the Ziehl-Neelsen method to determine the presence of acid-resistant and non-acid-resistant forms of mycobacteria, as well as to study the effect of pyrimidines and a comparison drug on structural changes in M.tuberculosis cells. Results. In the course of the study, the TAG4, TAG6, and TAG8 compounds were found to have the closest antibacterial activity to the comparison drug isoniazid, according to the indicator of mycobacteria growth retardation. The greatest bactericidal activity against M.tuberculosis was observed in TAG4, TAG7, and VMA–13–04. The remaining compounds have shown minimal inhibitory effect on the growth of M.tuberculosis. Microscopic studies have shown that under the influence of TAG3, TAG4, TAG7, TAG12, VMA-13-03, and VMA-13-04, the main structural components of M.tuberculosis cells undergo fragmentation and morphological changes compared to mycobacterium cells without exposure. Conclusion. As a result, it was found that all the studied compounds possess antimycobacterial activity. Compounds under the laboratory ciphers TAG1, TAG4, TAG7, and TAG13 were comparable to isoniazid by the nature of the inhibitory effect on the growth of M.tuberculosis, and the TAG3 compound even slightly exceeded the effect of the comparison drug. Compounds under the laboratory codes VMA-13-03, and VMA-13-04 had the least pronounced anti-tuberculosis effect. Compounds under the laboratory codes TAG5, TAG6, TAG11, and TAG12 showed the least antimycobacterial activity." @default.
• W4290391409 created "2022-08-07" @default.
• W4290391409 creator A5006084854 @default.
• W4290391409 creator A5019092285 @default.
• W4290391409 creator A5032164078 @default.
• W4290391409 creator A5043448424 @default.
• W4290391409 creator A5045651349 @default.
• W4290391409 creator A5064005941 @default.
• W4290391409 creator A5079952670 @default.
• W4290391409 creator A5088645184 @default.
• W4290391409 date "2022-08-04" @default.
• W4290391409 modified "2023-10-06" @default.
• W4290391409 title "Assessment of Antimycobacterial Activity of Newly Synthesized Pyrimidine Derivatives Against Mycobacterium tuberculosis" @default.
• W4290391409 cites W1868808028 @default.
• W4290391409 cites W1951631484 @default.
• W4290391409 cites W1967610149 @default.
• W4290391409 cites W1987181652 @default.
• W4290391409 cites W2011631825 @default.
• W4290391409 cites W2038405431 @default.
• W4290391409 cites W2061851297 @default.
• W4290391409 cites W2071182564 @default.
• W4290391409 cites W2083306545 @default.
• W4290391409 cites W2122125971 @default.
• W4290391409 cites W2137319201 @default.
• W4290391409 cites W2156258790 @default.
• W4290391409 cites W2303413353 @default.
• W4290391409 cites W2315368606 @default.
• W4290391409 cites W2333661524 @default.
• W4290391409 cites W2550091702 @default.
• W4290391409 cites W2585094719 @default.
• W4290391409 cites W2732995536 @default.
• W4290391409 cites W2763563055 @default.
• W4290391409 cites W2936188361 @default.
• W4290391409 cites W2963172656 @default.
• W4290391409 cites W3005895634 @default.
• W4290391409 cites W3014874297 @default.
• W4290391409 cites W4200523945 @default.
• W4290391409 cites W4211200024 @default.
• W4290391409 cites W4237275004 @default.
• W4290391409 doi "https://doi.org/10.37489/0235-2990-2022-67-3-4-4-15" @default.
• W4290391409 hasPublicationYear "2022" @default.
• W4290391409 type Work @default.
• W4290391409 citedByCount "0" @default.
• W4290391409 crossrefType "journal-article" @default.
• W4290391409 hasAuthorship W4290391409A5006084854 @default.
• W4290391409 hasAuthorship W4290391409A5019092285 @default.
• W4290391409 hasAuthorship W4290391409A5032164078 @default.
• W4290391409 hasAuthorship W4290391409A5043448424 @default.
• W4290391409 hasAuthorship W4290391409A5045651349 @default.
• W4290391409 hasAuthorship W4290391409A5064005941 @default.
• W4290391409 hasAuthorship W4290391409A5079952670 @default.
• W4290391409 hasAuthorship W4290391409A5088645184 @default.
• W4290391409 hasBestOaLocation W42903914091 @default.
• W4290391409 hasConcept C142724271 @default.
• W4290391409 hasConcept C185592680 @default.
• W4290391409 hasConcept C2777975735 @default.
• W4290391409 hasConcept C2779685592 @default.
• W4290391409 hasConcept C2780374374 @default.
• W4290391409 hasConcept C2781069245 @default.
• W4290391409 hasConcept C71924100 @default.
• W4290391409 hasConcept C86803240 @default.
• W4290391409 hasConcept C89423630 @default.
• W4290391409 hasConceptScore W4290391409C142724271 @default.
• W4290391409 hasConceptScore W4290391409C185592680 @default.
• W4290391409 hasConceptScore W4290391409C2777975735 @default.
• W4290391409 hasConceptScore W4290391409C2779685592 @default.
• W4290391409 hasConceptScore W4290391409C2780374374 @default.
• W4290391409 hasConceptScore W4290391409C2781069245 @default.
• W4290391409 hasConceptScore W4290391409C71924100 @default.
• W4290391409 hasConceptScore W4290391409C86803240 @default.
• W4290391409 hasConceptScore W4290391409C89423630 @default.
• W4290391409 hasIssue "3-4" @default.
• W4290391409 hasLocation W42903914091 @default.
• W4290391409 hasOpenAccess W4290391409 @default.
• W4290391409 hasPrimaryLocation W42903914091 @default.
• W4290391409 hasRelatedWork W1966448483 @default.
• W4290391409 hasRelatedWork W1994677231 @default.
• W4290391409 hasRelatedWork W2050953601 @default.
• W4290391409 hasRelatedWork W2099754252 @default.
• W4290391409 hasRelatedWork W2109375527 @default.
• W4290391409 hasRelatedWork W2170306976 @default.
• W4290391409 hasRelatedWork W2884095943 @default.
• W4290391409 hasRelatedWork W2953424608 @default.
• W4290391409 hasRelatedWork W3028438304 @default.
• W4290391409 hasRelatedWork W3210687582 @default.
• W4290391409 hasVolume "67" @default.
• W4290391409 isParatext "false" @default.
• W4290391409 isRetracted "false" @default.
• W4290391409 workType "article" @default.